Dallah Healthcare Co. · TADAWUL:4004
Dallah Healthcare — FY2024 Earnings Presentation
26 slides from Dallah Healthcare's earnings presentation, 2024
Slide 1: Dallah Healthcare Co. FY 2024
Dallah Healthcare Co. FY 2024
Slide 2: DHC's mission and vision guided by core values
DHC’s mission and vision … … guided by core values Mission Values To deliver excellent healthcare services Care and respect for our patients, which are consistent with our values and their needs and our society with the expectation of our patients, society, and partners Commitment to professional et
Slide 3: Dallah Healthcare Company offers an attractive investment opportunity
DHC has long been established in KSA and has shown year-on-year growth DHC has a strong product portfolio, consistently growing to address the evolving needs of patients Dallah Healthcare Company offers an DHC has numerous certifications positioning it at the forefront in terms of service excellence
Slide 4: History: long legacy in KSA healthcare and expansion
Dallah Hospital- 1987 Al Nakheel Dallah Pharma 2002 Dallah Ob-gyne 2007 2012 DHC listing Dallah Pediatrics 2013 Jordanian Pharmaceuticals Co. Afyaa Al Nakheel 2014 and DMRF North clinics 2015 quite rapidly both organically and inorganically Dallah Hospital- 2018 Namar Dallah Al Nakheel Meras Arabia
Slide 5: DHC owns and operates five categories of companies
Dallah Health Company Portfolio Today, DHC owns and directly operates five categories of companies while also engaging in active management of portfolio investments Owned & operated by DHC Portfolio investments (ownership share, %) Hospitals Clinics Dr. MRF Hospital Fully equipped private hospital,
Slide 6: Longstanding presence in KSA and integrated portfolio of services
12 +2,650 Healthcare Facilities Beds DHC’s longstanding presence in KSA and integrated portfolio of services position it +30% 48% Patients Volume CAGR Net Profit as a leader in service FY20-24 CAGR FY20-24 excellence, quality, and patient safety 5 +207 Medical specialities & sub- Cities arounk KSA s
Slide 7: Awards and Honours
“Ribbons 3” “Most Contributing Leading Hospital” By Newsweek (USA) in collaboration with CHI and Statista By CHI “The Joint Commission International “Excellence in Patient Satisfaction” (JCI) accreditation” Awards and Honours by the Global Patient Experience For Dallah Namar Hospital Organization “1
Slide 8: With +2,560 beds, DHC aims to further expand
Dallah Health Company Portfolio With +2,560 beds, DHC aims to further expand to meet future demand Combined current capacity at +2,560 beds across DHC's operational entities and investments Companies owned & operated by 540 300 475 274 3 2 beds beds beds beds Location Cities DHC Portfolio investment
Slide 9: Future Projects
Dallah Health Company Portfolio Future Projects Dallah Alarid Hospital Dallah Alnakheel Land Dallah Clinics • Land: 45,000 sqm • DHC, Dallah Real Estate, Aljazira Capital, • Built-up area: 87,300 sqm and Tatweer signed MoU to establish a private real estate fund. • 250 Beds • 3 Locations • An estima
Slide 10: DHC's presence over the Kingdom of Saudi Arabia
DHC's presence Al Khobar over the �)« Riyadh Al Hofouf Kingdom of ÷U�d�« ·uH�« Saudi Arabia Jeddah …b� Makkah W�dJ*« WJ� Abha UN�√ 9
Slide 11: Array of medical services across specialties
Dallah Health Company Portfolio The array of medical services offered by DHC hospitals extends across various specialties, complemented by supplementary support services 207+ Medical specialities and subspecialties 4+ key Ancillary Services Medical services under the following therapy areas: Supplem
Slide 12: Consistent patient volume growth
Dallah Health Company Portfolio Over the past 5 years, DHC's hospitals have demonstrated consistent patient volume growth Patient volume (in 000s) CAGR 3.7% 2,839 30.8% 2,737 2,252 1,800 968 2020 2021 2022 2023 2024 • MMC and KHCC was added from 2021 • Dallah Home Care and Dallah Clinics was added f
Slide 13: Certifications, accreditations and awards
Dallah Health Company Accreditations When addressing service excellence and patient safety, DHC has acquired several well-regarded certifications, accreditations, and awards One of the first hospitals in Dallah Hospital laboratory Dallah Hospitals catering Saudi Arabia awarded JCI certified by the C
Slide 14: DHC's Journey to Value-Based Healthcare
DHC’ Journey to Value-Based Healthcare DHC's is dedicated to leading the way in VBHC, ultimately delivering greater value and improved health outcomes for our patients Key initiatives: Pilot Programs Strategic Collaborations Future Focus • PROM & PREM with a Major Insurer • The Center for Value in H
Slide 15: Well-defined 5-year strategy for the diversified portfolio
Dallah Health Company Growth Strategy & Leadership DHC's future growth is supported by its well-defined 5-year strategy anchored around a coherent direction for the diversified portfolio Deep-dive included in the next slides Operating companies Investments Become a one-stop shop for VIP/A privately
Slide 16: Becoming a one-stop high-end service provider
Dallah Health Company Growth Strategy & Leadership To become a 'one-stop high-end' service provider, DHC will selectively specialize as well as expand into clinics, telemedicine, post-acute care and homecare Value One-stop-shop high-end provider First point of contact from the cradle to the grave Pr
Slide 17: Strong financial performance 2023 to 2024, 31% EPS growth
Dallah Health Company Financial Performance DHC has experienced a strong financial performance between year-2023 and year-2024, leading to 31% EPS growth Key consolidated financial metrics (SAR M) Year-2023 Year-2024 Revenues 2,943 8.9% 3,206 EBITDA 630 19.1% 751 EBIT 504 20.1% 610 Net Profit 385 26
Slide 18: Revenues over 5 years (1/5)
Dallah Health Company Financial Performance The trend of strong financial growth extends since 2020 and is supported by DHC's financial results over 5 years (1/5) Revenues (SAR M) CAGR 25% 8.9% 3,206 2,943 2,488 2,105 1,318 2020 2021 2022 2023 2024 17
Slide 19: Gross Profit over 5 years (2/5)
Dallah Health Company Financial Performance The trend of strong financial growth extends since 2020 and is supported by DHC's financial results over 5 years (2/5) Gross Profit (SAR M) CAGR 1400 11.9% 28% 38% 40% 36% 36% 37% 1200 34% 1207 35% 1000 1,079 30% 895 25% 800 760 20% 600 15% 400 450 10% 200
Slide 20: EBIT over 5 years (3/5)
Dallah Health Company Financial Performance The trend of strong financial growth extends since 2020 and is supported by DHC's financial results over 5 years (3/5) 900 30% EBIT (SAR M) 800CAGR 20.9% 45% 25% 700 19% 20% 600 17% 610 16% 16% 500 15% 504 11% 400 400 10% 300 334 5% 200 139 100 0% 2020 202
Slide 21: EBITDA over 5 years (4/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (4/5) EBITDA (SAR M) 30% 900 CAGR 19.1% 34% 800 25% 23% 21% 21% 21% 751 700 20% 18% 600 630 15% 500 514 449 400 10% 300 5% 200 234 100 0% 2020 2021 20
Slide 22: Net Profit over 5 years (5/5)
Dallah Health Company Financial Performance The trend of financial growth extends since 2020 and is supported by DHC's financial results over 5 years (5/5) Net Profit (SAR M) 900 30% CAGR 26% 48% 800 25% 700 600 20% 500 15% 485 15% 13% 13% 400 12% 385 300 10% 8% 295 275 200 5% 100 100 0 0% 2020 2021
Slide 23: Q3-2024 highest quarter ever in revenues
Dallah Health Company Financial Performance Q3-2024 highest Quarter ever in terms of revenues, seconded by Q4-2024 Revenues (SAR M) 848 806 809 784 765 750 717 670 Q1-2023 Q2-2023 Q3-2023 Q4-2023 Q1-2024 Q2-2024 Q3-2024 Q4-2024 22
Slide 24: Debt-to-EBITDA ratio decreasing year on year
Dallah Health Company Financial Performance As for its debt-to-EBITDA ratio, DHC is pursuing YoY decreases through more informed capital allocation strategies during its expansion Debt-to-EBITDA (M SAR) 6.5x 4.2x 3.8x 3.0x 2.5x 3.0x 2.5x 1,935 1,895 1897 1895 1897 1,867 1,515 751 751 630 630 514 449
Slide 25: Healthy return on equity averaging 13%
Dallah Health Company Financial Performance DHC achieved a healthy return on equity in the past 5 years, averaging 13%, despite the surge in the equity base Return on Equity (SAR M) 13.4% 13.7% 13.5% 13.4% 9.0% 2020 2021 2022 2023 2024 24
Slide 26: Thank you
Thank you